武 蕊,姚 彦,王 星,朱玉婷,黄牧坤,丁健超.苏黄止咳胶囊联合胸腺肽治疗老年慢阻肺合并肺部感染患者效果及对免疫功能、血气指标的影响[J].,2024,(11):2099-2103 |
苏黄止咳胶囊联合胸腺肽治疗老年慢阻肺合并肺部感染患者效果及对免疫功能、血气指标的影响 |
Effect of Suhuang Zhike Capsule Combined with Thymosin in the Treatment of Elderly Patients with COPD Complicated with Pulmonary Infection and Its Influence on Immune Function and Blood Gas Indexes |
投稿时间:2023-12-08 修订日期:2023-12-31 |
DOI:10.13241/j.cnki.pmb.2024.11.018 |
中文关键词: 苏黄止咳胶囊 胸腺肽 老年慢阻肺 肺部感染 |
英文关键词: Suhuang Zhike capsule Thymosin Senile COPD Lung infection |
基金项目:陕西省重点研发计划项目(2021SF-044) |
|
摘要点击次数: 106 |
全文下载次数: 80 |
中文摘要: |
摘要 目的:探讨苏黄止咳胶囊联合胸腺肽治疗老年慢阻肺合并肺部感染患者效果及对免疫功能、血气指标的影响。方法:将80例于医院进行治疗的老年患者作为研究对象,患者均确诊为慢阻肺疾病,且均合并肺部感染。患者入院时间分布在2020年9月至2023年9月范围内,根据治疗方式的不同对患者进行分组,其中40例患者分为对照组,在常规对症治疗基础上增加胸腺肽治疗,另外40例患者分为观察组,在对照组基础上增加苏黄止咳胶囊治疗。对比两组临床治疗总有效率、炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]、免疫功能[CD3+、CD4+/CD8+、自然杀伤细胞(NK)]、血气指标[二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)、酸碱度(pH)]、不良反应发生情况[恶心呕吐、头晕、皮疹、腹泻]。结果:观察组治疗总有效率高于对照组(P<0.05)。接受治疗之后,观察组CRP、TNF-α水平均明显低于对照组(P<0.05)。治疗后,观察组CD3+、CD4+/CD8+、NK水平较对照组高(P<0.05)。接受治疗之后,观察组PaCO2指标水平明显比对照组低(P<0.05),观察组PaO2、pH指标水平明显比对照组高(P<0.05)。统计两组恶心呕吐、头晕、皮疹、腹泻等不良反应总发生率,观察组为2.50%,对照组为7.50%,两组不良反应总发生率比较无差异(P>0.05)。结论:老年慢阻肺合并肺部感染患者在常规对症治疗和胸腺肽治疗的基础上增加苏黄止咳胶囊治疗,可明显提升临床治疗总有效率,改善炎性因子水平和血气指标,提升免疫功能,且不会增加不良反应发生风险。 |
英文摘要: |
ABSTRACT Objective: To investigate the effect of Suhuang Zhike capsule combined with thymosin in the treatment of elderly patients with COPD complicated with pulmonary infection and its influence on immune function and blood gas indexes. Methods: 80 elderly patients treated in hospital were studied. All patients were diagnosed with COPD disease and were complicated with pulmonary infection. The admission time of the patients was distributed from September 2020 to September 2023, and the patients were divided into groups according to different treatment methods, among which 40 patients were divided into matched group and thymosin treatment was added on the basis of conventional symptomatic treatment, and the other 40 patients were divided into observation group and Suhuang Zhike capsule was added on the basis of matched group. Compared the total therapeutic effective rate, inflammatory factors [C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α)] of the two groups, immune function [CD3+, CD4+/CD8+, Natural killer cell, NK)], blood gas index [partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen oxygen, PaO2), pH], occurrence of adverse reactions [nausea, vomiting, dizziness, rash, diarrhea]. Results: The total response rate in the observation group was higher than that in the matched group (P<0.05). Post-treatment, the CRP and TNF- α levels in the observation group were significantly lower than those in the matched group (P<0.05). Post-treatment, the levels of CD3+, CD4+/CD8+, and NK were higher in the observation group than in the matched group (P<0.05). After receiving treatment, the PaCO2 index level in the observation group was lower than that in the matched group (P<0.05), and the level of PaO2 and pH index in the observation group was higher than that in the matched group (P<0.05). The total incidence of adverse reactions such as nausea, vomiting, dizziness, rash and diarrhea in the two groups was 2.50% in the observation group and 7.50% in the matched group. There was no difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: In elderly patients with COPD complicated with pulmonary infection, the addition of Suhuang Zhike capsule on the basis of conventional symptomatic treatment and thymosin treatment can significantly improve the total effective rate of clinical treatment, improve the level of inflammatory factors and blood gas indexes, and enhance immune function, without increasing the risk of adverse reactions. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|